Sterile injectables · Contract manufacturing in India

Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion

Request manufacturing feasibility

Discuss third-party manufacturing of Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion with Walter Healthcare, India. Share your target market, required container count and infusion volume, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-0017
Composition and strength
Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml
Dosage form
Infusion
Indicative administration route
Parenteral
Therapeutic navigation area
Nutrition & supportive care
Pharmacological class
Nutritional & supportive-care agent
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: Riboflavin. The references below cover only the named ingredients.

Prescribing-label excerpts

Ascorbic Acid

Reference for: Ascorbic Acid. Source presentation: injection. Source route: intravenous.

Mechanism of action

The exact mechanism of action of ascorbic acid for the treatment of symptoms and signs of scurvy (a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to restore the body pool of ascorbic acid.

Pharmacokinetics

In a single pharmacokinetic study, healthy male and female adults (n=8) were given a single intravenous dose of 1000 mg ascorbic acid (5 times the largest recommended single dose) infused over a 30 minute period. The mean peak exposure to ascorbic acid was 436.2 μM and occurred at the end of the 30 minute infusion.

Distribution — Ascorbic acid is distributed widely in the body, with large concentrations found in the liver, leukocytes, platelets, glandular tissues, and lens of the eye. Based on data from oral exposure, ascorbic acid is known to be distributed into breast milk and crosses the placental barrier.

Elimination — When the body is saturated with ascorbic acid, the plasma concentration will be about the same as that of the renal threshold; if further amounts are then administered, most of it is excreted in the urine. When body tissues are not saturated and plasma concentration is low, administration of ascorbic acid results in little or no renal excretion. The mean±SD (N=3) half-life observed in the single dose PK study, as described above, was 7.4±1.4 h.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Ascorbic Acid — injection

Reference accessed . Label revision: 2025-12-17.

Ingredient-level reference

Nicotinamide (intravenous vitamin reference)

Reference for: Nicotinamide. Source presentation: MULTIVITAMIN INFUSION. Source route: intravenous.

Mechanism of action

Nicotinamide contributes to NAD and NADP coenzymes involved in cellular oxidation-reduction reactions.

Pharmacokinetics

The intravenous multivitamin reference describes plasma vitamin B3 in acid or amide forms and urinary elimination as unchanged substance or metabolites. It does not provide a nicotinamide-specific half-life or validate another injection mixture.

Ingredient-level summary of the cited reference product. Study formulation, route, strength and population govern interpretation; these data do not establish pharmacokinetics or bioequivalence for Walter's formulation or fixed combination.

Source: France ANSM: Cernevit, nicotinamide component, sections 5.1–5.2

Reference accessed .

Prescribing-label excerpts

Thiamine Hydrochloride

Reference for: Thiamine. Source presentation: injection, solution. Source route: intramuscular; intravenous.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

The water soluble vitamins are widely distributed in both plants and animals. They are absorbed in man by both diffusion and active transport mechanisms. These vitamins are structurally diverse (derivatives of sugar, pyridine, purines, pyrimidine, organic acid complexes and nucleotide complex) and act as coenzymes, as oxidation-reduction agents, possibly as mitochondrial agents. Metabolism is rapid, and the excess is excreted in the urine.

Thiamine is distributed in all tissues. The highest concentrations occur in liver, brain, kidney and heart. When thiamine intake is greatly in excess of need, tissue stores increase two to three times. If intake is insufficient, tissues become depleted of their vitamin content. Absorption of thiamine following IM administration is rapid and complete.

Thiamine combines with adenosine triphosphate (ATP) to form thiamine pyrophosphate, also known as cocarboxylase, a coenzyme. Its role in carbohydrate metabolism is the decarboxylation of pyruvic acid in the blood and α-ketoacids to acetaldehyde and carbon dioxide. Increased levels of pyruvic acid in the blood indicate vitamin B1 deficiency.

The requirement for thiamine is greater when the carbohydrate content of the diet is raised. Body depletion of vitamin B1 can occur after approximately three weeks of total absence of thiamine in the diet.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Thiamine Hydrochloride — injection, solution

Reference accessed . Label revision: 2026-07-31.

Prescribing-label excerpts

Dextrose Monohydrate

Reference for: Dextrose. Source presentation: injection, solution. Source route: intravenous.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

Dextrose restores blood glucose levels and provides a source of carbohydrate calories.

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dextrose have not been fully characterized.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Dextrose Monohydrate — injection, solution

Reference accessed . Label revision: 2026-07-13.

Prescribing-label excerpts

Pyridoxine Hydrochloride

Reference for: Pyridoxine. Source presentation: injection, solution. Source route: intramuscular; intravenous.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

Natural substances that have vitamin B 6 activity are pyridoxine in plants and pyridoxal or pyridoxamine in animals. All 3 are converted to pyridoxal phosphate by the enzyme pyridoxal kinase. The physiologically active forms of vitamin B 6 are pyridoxal phosphate (codecarboxylase) and pyridoxamine phosphate. Riboflavin is required for the conversion of pyridoxine phosphate to pyridoxal phosphate.

Vitamin B 6 acts as a coenzyme in the metabolism of protein, carbohydrate, and fat. In protein metabolism, it participates in the decarboxylation of amino acids, conversion of tryptophan to niacin or to serotonin (5-hydroxtryptamine), deamination, and transamination and transulfuration of amino acids. In carbohydrate metabolism, it is responsible for the breakdown of glycogen to glucose-1-phosphate.

The total adult body pool consists of 16 to 25 mg of pyridoxine. Its half-life appears to be 15 to 20 days. Vitamin B 6 is degraded to 4-pyridoxic acid in the liver. This metabolite is excreted in the urine.

The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B 6 deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1.25 mg. The ‘‘Recommended Dietary Allowance’’ of the National Academy of Sciences is estimated to be as much as 2.2 mg for adults and 2.5 mg for pregnant and lactating women. The requirements are more in persons having certain genetic defects or those being treated with isonicotinic acid hydrazide (INHJ) or oral contraceptives.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Pyridoxine Hydrochloride — injection, solution

Reference accessed . Label revision: 2024-10-15.

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Review the complete infusion system

Listed presentation: Infusion.

Connect the proposed concentration and container volume with the intended bag or bottle, closure and any administration components in scope. Plan the appropriate compatibility and stability work around that system. Keep preparation and dilution instructions open until product-specific evidence supports the final presentation.

Translate the listed strength into a quantitative formula

Strength expressions in this entry include “500 mg”, “1000 mg”, “160 mg”, “50 mg”, “4 mg”, with further amounts in the full composition.

Tie every stated ingredient amount to its intended dosage unit or measure, then distinguish that declared amount from the quantity of raw material needed for a batch. Record any assay or equivalence calculation in the formula. This gives development, purchasing and artwork teams the same strength definition without assigning a patient dose from the catalogue.

Suggested starting point

A practical starting point is to translate the listed strength into a quantitative formula. For this infusion brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the infusion presentation.

Use this preparation guide for Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

State concentration, total fill volume, intended route and proposed container system. Confirm that the requested presentation fits the available site and equipment scope.

Quality & technical transfer

Request review of the sterile-process strategy, applicable release testing, container-closure integrity and supporting stability information for the proposed infusion pack.

Review the technical documents

Packaging configuration

Specify the proposed bottle or bag, closure or ports, overwrap and secondary pack. Identify any administration-set requirement separately.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Concentration and pack size
The record includes a concentration or percentage expression. Confirm its complete basis, then specify the finished fill volume or weight separately. Do not treat pack size as the strength.

Quantities, MOQ & lead time

For Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion (WH-0017), state the container count and infusion volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion

What is listed in the catalogue?

The catalogue lists Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml as infusion in its nutrition & supportive care navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, infusion presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Ascorbic Acid 500 mg, Dextrose 1000 mg, Nicotinamide 160 mg / 5 ml, Pyridoxine 50 mg, Riboflavin 4 mg, Thiamine 250 mg / 5 ml Infusion is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .